Australia Markets open in 8 hrs 21 mins

Why these ASX cannabis shares are starting the week on a high

James Mickleboro
marijuana leaf with upward facing arrow

The MGC Pharmaceuticals Ltd (ASX: MXC) share price is starting the week on a high.

In morning trade the cannabis company’s shares are up 3% to 3.8%. They were up as much as 8% at one stage.

Why is the MCG Pharma share price on a high?

Investors have responded positively to an announcement this morning which revealed that it has entered into a supply agreement with THC Global Group Ltd (ASX: THC).

According to the release, MGC Pharma will provide THC Global with an immediate supplementary source of medicinal cannabis products. These products will then be packaged and made available to patients under its Canndeo brand.

THC Global expects these products to launch in Australia and New Zealand during the first quarter of calendar year 2020.

The agreement also provides for the two companies to collaborate on the future supply of active pharmaceutical ingredients (API) extracts as well as other finished products. This includes product from THC Global’s Southport Facility.

MGC Pharma’s managing director and CEO, Roby Zomer, was pleased with the agreement.

He said: “We are pleased to partner with THC Global to produce and supply white label Canndeo branded phytocannabinoid products. With the ever-growing use of phytocannabinoids for medicinal purposes, MGC Pharma is well placed to work with companies such as THC Global to manufacture quality and cost effective phytocannabinoid products.”

“We expect that further discussions between MGC Pharma and THC Global on mutual exports of product to respective international markets will be beneficial to all going forward, particularly as we develop our ~15,000m2 GMP compliant pharma production and research facility in Malta,” he added.

THC Global licence update.

Shortly before the market open THC Global requested a trading halt.

According to the release, it requested the trading halt pending an announcement relating to the receipt of a licence to manufacture therapeutic goods from the Australian Therapeutic Goods Administration.

This would be a big positive for the company and could mean it shoots higher along with MGC Pharma when it returns to trade.

The post Why these ASX cannabis shares are starting the week on a high appeared first on Motley Fool Australia.

Not sure about cannabis shares? Then don't miss out on these growth shares that could outperform them in 2020.

NEW. The Best 5 Growth Shares to Buy Today!….

Our Motley Fool experts have just released a fantastic report, detailing 5 dirt cheap shares that you can buy in 2020.

One stock is an Australian internet darling with a rock solid reputation and an exciting new business line that promises years (or even decades) of growth… while trading at an ultra-low price…

Another is a diversified conglomerate trading near a 52-week low all while offering a 2.7% fully franked yield...

Plus 3 more cheap bets that could position you to profit over the next 12 months!

See for yourself now. Simply click the link below to scoop up your FREE copy and discover all 5 shares. But you will want to hurry – this free report is available for a brief time only.

CLICK HERE FOR YOUR FREE REPORT!

More reading

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Motley Fool's purpose is to help the world invest, better. Click here now for your free subscription to Take Stock, The Motley Fool's free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson. 2020